Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Radiation Oncology Journal ; : 265-275, 2018.
Article in English | WPRIM | ID: wpr-741964

ABSTRACT

Cancer is a complex multifaceted illness that affects different patients in discrete ways. For a number of cancers the use of chemotherapy has become standard practice. Chemotherapy is a use of cytostatic drugs to cure cancer. Cytostatic agents not only affect cancer cells but also affect the growth of normal cells; leading to side effects. Because of this, radiotherapy gained importance in treating cancer. Slaughtering of cancerous cells by radiotherapy depends on the radiosensitivity of the tumor cells. Efforts to improve the therapeutic ratio have resulted in the development of compounds that increase the radiosensitivity of tumor cells or protect the normal cells from the effects of radiation. Amifostine is the only chemical radioprotector approved by the US Food and Drug Administration (FDA), but due to its side effect and toxicity, use of this compound was also failed. Hence the use of herbal radioprotectors bearing pharmacological properties is concentrated due to their low toxicity and efficacy. Notably, in silico methods can expedite drug discovery process, to lessen the compounds with unfavorable pharmacological properties at an early stage of drug development. Hence a detailed perspective of these properties, in accordance with their prediction and measurement, are pivotal for a successful identification of radioprotectors by drug discovery process.


Subject(s)
Humans , Amifostine , Computer Simulation , Cytostatic Agents , Drug Discovery , Drug Therapy , Quantitative Structure-Activity Relationship , Radiation Tolerance , Radiotherapy , United States Food and Drug Administration
2.
Article in English | IMSEAR | ID: sea-154551

ABSTRACT

Radiotherapy is regarded as one of the most important therapeutic modality for the treatment of malignant lesions. This field is undergoing rapid advancements in the recent times. With the use of radiosensitizers and radioprotective agents, the course of radiotherapy has improved the sensitization of tumor cells and protection of normal cells, respectively. The aim of this paper was to critically review and analyze the available compounds used as radiosensitizers, radioprotectors, and radiation mitigators. For reviewing, the author used the electronic search for the keywords 'Radiosensitizers', 'Radioprotectors', 'Radiation mitigators' on PubMed for inclusion of previously published articles and further search of reference papers on individual radiosensitizing and radioprotecting agents was done. Radiosensitizers are agents that sensitize the tumor cells to radiation. These compounds apparently promote fixation of the free radicals produced by radiation damage at the molecular level. The mechanism of action is similar to the oxygen effect, in which biochemical reactions in the damaged molecules prevent repair of the cellular radiation damage. Free radicals such as OH + are captured by the electron affinity of the radiosensitizers, rendering the molecules incapable of repair. Radioprotectors are compounds that are designed to reduce the damage in normal tissues caused by radiation. These compounds are often antioxidants and must be present before or at the time of radiation for effectiveness. Other agents, termed mitigators, may be used to minimize toxicity even after radiation has been delivered. This article tries to discuss the various aspects of radiosensitizers, radioprotectors, and radiation mitigators including the newer agents.


Subject(s)
Neoplasms/radiotherapy , Radiation-Protective Agents/therapeutic use , Radiation-Sensitizing Agents/therapeutic use , Radiotherapy/methods
3.
Article in English | IMSEAR | ID: sea-153924

ABSTRACT

In the field of medicine or dentistry, cancer is one of the most common causes for death of the individual worldwide, in which oral cancer accounts for about 10% of it. One of the most important treatment modalities for cancer includes radiotherapy. During radiotherapy, exposure of the normal tissue to these ionizing radiations, results in mutagenesis and cell death. Several modalities and clinical approaches have been made to reduce these early and late complications of the radiotherapies and one among them is, by the means of pharmacological agents. Many experimental and clinical studies have given rise to new concepts of chemical and molecular pharmacological agents that could be effective in protection and treatment of radiation damage to surrounding normal tissues. Clinical Significance: To reduce the significant complications in irradiated patients, the clinical implication of these radioprotective agents have emerged as potential drugs and with anti-tumour effect in the radiotherapy of various cancers including oral carcinomas.

SELECTION OF CITATIONS
SEARCH DETAIL